Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Keegan · SciRah

Researcher profile · Semantic Scholar

P. Keegan

Share profile

P. Keegan — researcher profile on SciRah

h-index: 59
Works: 141
Citations: 12K

Most-cited papers

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
L. Marcus, S. Lemery, P. Keegan, R. Pazdur
2019Clinical Cancer Research991 citations Open access
Semantic Scholar
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.
S. Lemery, P. Keegan, R. Pazdur
2017New England Journal of Medicine557 citations
Semantic Scholar
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Zi-Xian Wang, C. Cui, Jun Yao, Yan-Qiao Zhang +77 more
2022Cancer Cell471 citations Open access
Semantic Scholar
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
D. Kazandjian, D. Suzman, G. Blumenthal, Sirisha L. Mushti +4 more
2016The Oncologist423 citations Open access
Semantic Scholar
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
H. Mai, Qiu-Yan Chen, Dong-Ping Chen, Chao-Su Hu +33 more
2021Nature Medicine350 citations
Semantic Scholar
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1
J. Sul, G. Blumenthal, Xiao-Ping Jiang, Kun He +2 more
2016The Oncologist341 citations Open access
Semantic Scholar
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms
P. Kluetz, A. Slagle, Elektra J. Papadopoulos, L. Johnson +8 more
2016Clinical Cancer Research291 citations
Semantic Scholar
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
D. Kazandjian, G. Blumenthal, Huan-Yu Chen, Kun He +4 more
2014The Oncologist283 citations Open access
Semantic Scholar
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review
J. Beaver, L. Howie, L. Pelosof, Tamy Kim +8 more
2018JAMA Oncology277 citations
Semantic Scholar
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
Pai-Scherf Lee, G. Blumenthal, Hong-Shan Li, Sriram Subramaniam +9 more
2017The Oncologist269 citations Open access
Semantic Scholar
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
L. Odogwu, Luckson N. Mathieu, G. Blumenthal, E. Larkins +10 more
2018The Oncologist217 citations Open access
Semantic Scholar
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation–Positive Non–Small Cell Lung Cancer
D. Kazandjian, G. Blumenthal, Weishi Yuan, Kun He +2 more
2016Clinical Cancer Research208 citations
Semantic Scholar
Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
D. Kazandjian, Yu-Tao Gong, P. Keegan, R. Pazdur +1 more
2019JAMA Oncology206 citations Open access
Semantic Scholar
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
G. Blumenthal, Stella Karuri, Hui Zhang, Li-Jun Zhang +6 more
2015Journal of Clinical Oncology206 citations Open access
Semantic Scholar
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy
E. Larkins, G. Blumenthal, Weishi Yuan, Kun He +9 more
2017The Oncologist201 citations Open access
Semantic Scholar
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
L. Fashoyin-Aje, M. Donoghue, Huan-Yu Chen, Kun He +5 more
2018The Oncologist194 citations Open access
Semantic Scholar
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
G. Blumenthal, P. Bunn, J. Chaft, C. McCoach +39 more
2018Journal of Thoracic Oncology164 citations Open access
Semantic Scholar
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
M. Axelson, Ke Liu, Xiao-Ping Jiang, Kun He +9 more
2013Clinical Cancer Research161 citations
Semantic Scholar
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)
Zhi-Jie Wang, Lin Wu, Bao-Lan Li, Ying Cheng +63 more
2022Journal of Clinical Oncology158 citations Open access
Semantic Scholar
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer
S. Khozin, G. Blumenthal, Li-Jun Zhang, Sheng-Hui Tang +16 more
2015Clinical Cancer Research154 citations Open access
Semantic Scholar
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hong-Shan Li, Jingyu Yu, Chao Liu, Jiang Liu +14 more
2017Journal of Pharmacokinetics and Pharmacodynamics138 citations
Semantic Scholar
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab
M. Hazarika, Meredith K. Chuk, M. Theoret, Sirisha L. Mushti +14 more
2017Clinical Cancer Research130 citations Open access
Semantic Scholar
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
S. Khozin, G. Blumenthal, Xiao-Ping Jiang, Kun He +5 more
2014The Oncologist127 citations Open access
Semantic Scholar
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non–Small Cell Lung Cancer Following Crizotinib
E. Larkins, G. Blumenthal, Huan-Yu Chen, Kun He +13 more
2016Clinical Cancer Research125 citations
Semantic Scholar
An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
J. Beaver, M. Hazarika, Flora Mulkey, Sirisha L. Mushti +13 more
2018The Lancet Oncology120 citations Open access
Semantic Scholar
FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors
L. Marcus, M. Donoghue, Stephanie L Aungst, C. Myers +6 more
2020Clinical Cancer Research112 citations Open access
Semantic Scholar
FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma
Denise Casey, S. Demko, S. Shord, Hong Zhao +6 more
2017Clinical Cancer Research109 citations
Semantic Scholar
FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
S. Marur, H. Singh, P. Mishra-Kalyani, E. Larkins +4 more
2018Seminars in Oncology95 citations
Semantic Scholar
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.
D. Kazandjian, P. Keegan, D. Suzman, R. Pazdur +1 more
2017Seminars in Oncology90 citations
Semantic Scholar
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials: A Meta-analysis
G. Blumenthal, Li-Jun Zhang, Hui Zhang, D. Kazandjian +6 more
2017JAMA Oncology86 citations Open access
Semantic Scholar
Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Elaine Chang, L. Pelosof, S. Lemery, Yu-Tao Gong +14 more
2021The Oncologist83 citations Open access
Semantic Scholar
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma
A. Barone, M. Hazarika, M. Theoret, P. Mishra-Kalyani +11 more
2017Clinical Cancer Research80 citations Open access
Semantic Scholar
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma
Meredith K. Chuk, Jennie Chang, M. Theoret, E. Sampene +13 more
2017Clinical Cancer Research80 citations
Semantic Scholar
FDA Approval Summary: Ramucirumab for Gastric Cancer
S. Casak, Ibilola Fashoyin-Aje, S. Lemery, Lillian Zhang +14 more
2015Clinical Cancer Research80 citations Open access
Semantic Scholar
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Abhilasha Nair, K. Reece, M. Donoghue, Weishi Yuan +3 more
2020The Oncologist77 citations Open access
Semantic Scholar
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Flora Mulkey, M. Theoret, P. Keegan, R. Pazdur +1 more
2020Journal for ImmunoTherapy of Cancer72 citations Open access
Semantic Scholar
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
A. Barone, Dow-Chung Chi, M. Theoret, Huan-Yu Chen +9 more
2017Clinical Cancer Research71 citations Open access
Semantic Scholar
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer
Abhilasha Nair, S. Lemery, Jun Yang, Anshu Marathe +12 more
2015Clinical Cancer Research71 citations Open access
Semantic Scholar
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy
C. McCoach, G. Blumenthal, L. Zhang, A. Myers +6 more
2017Annals of Oncology68 citations Open access
Semantic Scholar
Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer
S. Khozin, C. Weinstock, G. Blumenthal, Joyce Cheng +7 more
2016Clinical Cancer Research66 citations
Semantic Scholar
FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
L. Odogwu, Luckson N. Mathieu, K. Goldberg, G. Blumenthal +11 more
2017The Oncologist65 citations Open access
Semantic Scholar
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma
J. Beaver, M. Theoret, Sirisha L. Mushti, Kun He +6 more
2017Clinical Cancer Research58 citations
Semantic Scholar
Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer.
Martin H. Cohen, Huan-Yu Chen, S. Shord, C. Fuchs +5 more
2013The Oncologist58 citations Open access
Semantic Scholar
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
X. Sheng, Hai-Ge Chen, B. Hu, Xudong Yao +18 more
2021Clinical Cancer Research57 citations Open access
Semantic Scholar
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
D. Kazandjian, S. Khozin, G. Blumenthal, Li-Jun Zhang +6 more
2016JAMA Oncology53 citations Open access
Semantic Scholar
FDA Approval Summary: TAS-102
L. Marcus, S. Lemery, S. Khasar, E. Wearne +12 more
2017Clinical Cancer Research47 citations
Semantic Scholar
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen
C. Osgood, Meredith K. Chuk, M. Theoret, Lan Huang +4 more
2017Clinical Cancer Research42 citations Open access
Semantic Scholar
U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
E. Larkins, Barbara Scepura, G. Blumenthal, E. Bloomquist +5 more
2015The Oncologist40 citations Open access
Semantic Scholar
Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.
C. McCoach, G. Blumenthal, L. Zhang, A. Myers +6 more
2019Annals of Oncology39 citations Open access
Semantic Scholar
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma.
Diana Bradford, S. Demko, Susan Jin, P. Mishra-Kalyani +6 more
2020The Oncologist33 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Pazdur×42
Invite
R. Pazdur — researcher profile on SciRah
G. Blumenthal×26
Invite
G. Blumenthal — researcher profile on SciRah
Kun He×23
Invite
Kun He — researcher profile on SciRah
Hong Zhao×17
Invite
Hong Zhao — researcher profile on SciRah

×15

Invite

R. Sridhara — researcher profile on SciRah

K. Goldberg×12

Invite

K. Goldberg — researcher profile on SciRah

D. Kazandjian×10

Invite

D. Kazandjian — researcher profile on SciRah

Whitney S. Helms×10

Invite

Whitney S. Helms — researcher profile on SciRah

Huan-Yu Chen×9

Invite

Huan-Yu Chen — researcher profile on SciRah

Invite

M. Theoret — researcher profile on SciRah

Invite

S. Lemery — researcher profile on SciRah

Amy E. McKee×7

Invite

Amy E. McKee — researcher profile on SciRah